Autonomic nervous system and lipid metabolism: findings in anxious-depressive spectrum and eating disorders

Elisabetta Pistorio¹, Maria Luca¹, Antonina Luca², Vincenzo Messina¹ and Carmela Calandra¹*

Abstract

Objective: To correlate lipid metabolism and autonomic dysfunction with anxious-depressive spectrum and eating disorders. To propose the lipid index (LI) as a new possible biomarker.

Methods: 95 patients and 60 controls were enrolled from the University Psychiatry Unit of Catania and from general practitioners (GPs). The patients were divided into four pathological groups: Anxiety, Depression, Anxious-Depressive Disorder and Eating Disorders [Diagnostic and Statistical Manual of Mental Disorders Fourth Edition Text Revision (DSM-IV-TR) official/appendix criteria]. The levels of the cholesterol, triglycerides and apolipoproteins A and B were determined. The LI, for each subject, was obtained through a mathematical operation on the values of the cholesterol and triglycerides levels compared with the maximum cut-off of the general population. The autonomic functioning was tested with Ewing battery tests. Particularly, the correlation between heart rate variability (HRV) and lipid metabolism has been investigated.

Results: Pathological and control groups, compared among each other, presented some peculiarities in the lipid metabolism and the autonomic dysfunction scores. In addition, a statistically significant correlation has been found between HRV and lipid metabolism.

Conclusions: Lipid metabolism and autonomic functioning seem to be related to the discussed psychiatric disorders. LI, in addition, could represent a new possible biomarker to be considered.

Keywords: depression, anxiety, anxious-depressive disorder, eating disorders, lipid metabolism, autonomic nervous system functioning, lipid index

Background

The dysfunctions of lipid metabolism and autonomic nervous system have been found to be linked with anxious-depressive spectrum and eating disorders [1-19], but no definitive conclusions has yet been reached.

The aim of this work is to correlate the levels of cholesterol, triglycerides, apolipoproteins A-B, LI and autonomic dysfunction to depression, anxiety, anxious-depressive disorder and eating disorders. In addition, the correlation between HRV and lipid metabolism has been tested.
diagnoses were formulated according to the criteria of the DSM-IV-TR (official/appendix criteria) [20].

Figure 1 shows the distribution of the pathological groups.

The autonomic nervous system (ANS) functioning was evaluated with the Ewing battery of tests through an electrocardiograph and a sphygmomanometer; particularly: Deep Breathing, Lying-to-Standing, Valsalva Manoeuvre and Sustained Handgrip tests [21,22]. Scores from 1 (mild) to 5 (severe) were considered parameters of autonomic dysfunction, passing through intermediate values of severity [23].

Particularly, the correlation between HRV (time-domain method) and lipid metabolism has been investigated.

Table 1

| Group                        | N   | %    | Age  |
|------------------------------|-----|------|------|
| Depression                   | 39  | 50 % | 50 ± 14.8 |
| M                            | 9   | 23%  | 498 ± 14.3 |
| F                            | 30  | 77%  | 50 ± 14.0 |
| Anxiety                      | 28  | 57%  | 480 ± 17.7 |
| M                            | 16  | 57%  | 486 ± 16.2 |
| F                            | 12  | 43%  | 471 ± 20.2 |
| Anxious-depressive disorder  | 13  | 54%  | 466 ± 13.8 |
| M                            | 6   | 54%  | 528 ± 10.6 |
| F                            | 7   | 46%  | 414 ± 14.7 |
| Eating Disorders             | 15  | 31.3%| 31.3 ± 7.06 |
| M                            | 1   | 7%   | 24 |
| F                            | 14  | 93%  | 31.8 ± 7.02 |
| Controls                     | 60  | 50.5%| 50.6 ± 10.8 |
| M                            | 36  | 60%  | 50.6 ± 9.9 |
| F                            | 24  | 40%  | 50.3 ± 12.3 |

Legend: The table shows data regarding the male (M) and female (F) distribution within every group, in number (N) and percentage (%). In addition, age is reported, referring to the whole group and to the gender (mean age and standard deviation (±)).

Cholesterol, triglycerides and apolipoproteins A and B were analyzed through fasting blood samples. All the analyses were repeated three times.

Normal fasting rates of triglycerides range from 50 to 160 mg/dl; normal fasting rates of cholesterol range from 100 to 200 mg/dl [24].

All the subjects’ rates of cholesterol and triglycerides were compared to the maximum cut-off of the general population (subject cholesterolemia/200; subject trigliceridemia/160) thus creating two ratios: cholesterol index (CI) and triglycerides index (TI).

Through the operation CI - TI the LI was obtained. A positive index number means that the cholesterol production is prevalent, while a negative one indicates a prevalent triglycerides production.

A value of + 0.15 or - 0.15 could be taken as 0, since it could be considered an irrelevant nutritional variation.

Data analysis

The Statistical Package for Social Sciences (SPSS, 2000) was used. T-test and Z test were used. The association between categorical descriptive variables was tested through paired-samples t-test.

Mann-Whitney test was used to compare the results regarding the Ewing score. Pearson correlation has been performed to find possible correlations between HRV and lipid metabolism. The p values were then obtained with t-test. Values of p ≤ 0.05, < 0.01 and < 0.001 were considered statistically significant.

Results

Lipid Metabolism

Cholesterol

The anxious-depressive disorder group, compared to all the other groups (anxiety: t = 2.27, p < 0.025; depression: t = 3.42, p < 0.005; ED: t = 2.94, p < 0.005), and to the
control group ($t = 1.75, p < 0.05$), presented lower levels of cholesterol.

With regards to the other groups, their cholesterol levels were higher compared to the control group, but there was not a statistically significant difference between the pathological groups compared among each other.

**Triglycerides**

The anxiety and anxious-depressive disorder groups, compared among each other, did not present a statistically significant difference in the triglycerides levels, but they both presented significantly higher triglycerides levels compared to all the other groups and to the control group (the anxiety group versus: depression: $t = 4.5, p < 0.005$; ED: $t = 6.31, p < 0.05$; control group: $t = 5.41, p < 0.005$); (the anxious-depressive disorder group versus: depression: $t = 6.7, p < 0.005$; ED $t = 10.7, p < 0.005$; control group: $t = 2.91, p < 0.005$).

The depression group presented lower triglycerides levels, when compared to anxiety, anxious-depressive disorder and control groups ($Z = 4.46, p < 0.001$); higher triglycerides levels, when compared to the eating disorders group ($t = 3.36, p < 0.005$), which presented lower triglycerides levels than in all the pathological and control groups ($t = 8.31, p < 0.005$).

LI

The eating disorders group presented the highest LI among the pathological and control groups (depression: $t = 4.75, p < 0.005$; anxiety: $t = 5.87, p < 0.005$; anxious-depressive disorders: $t = 14, p < 0.005$; control group: $t = 12.5, p < 0.005$). The LI, among the anxiety and anxious-depressive disorder groups, did not present a statistically significant difference, but it was significantly lower than that of the control group and of the other pathological groups ($t = 2, p < 0.05$). In terms of average, the anxious-depressive disorder group presented the lowest LI of the whole sample of the study.

The depression group presented, therefore, a higher LI than did the anxiety ($t = 3.5, p < 0.005$) and anxious-depressive disorder groups ($t = 9.25, p < 0.005$), but did not present a statistically significant difference compared to the control group.

**Apolipoproteins A and B**

The general population maximum cut-off was not exceeded either in the pathological groups or in the control one. Nevertheless, the anxious-depressive disorder group presented higher levels of Apolipoproteins A, compared to the other groups and to the control group. This same pattern was observed for Apolipoproteins B, only in the anxiety group.

For more details about the results regarding lipid metabolism, see Table 2.

**Autonomic Nervous System Functioning**

Among the pathological groups, the most represented autonomic dysfunctions were at a mild-mild/moderate level (see Figure 2). Among the control group, 51.7% did not present autonomic dysfunctions, 33.3% presented mild dysautonomia and 15.0% presented mild/moderate dysautonomia. In contrast to the pathological groups, the control group did not present other, more severe, dysautonomia levels. All the pathological groups presented a statistically significant difference compared to the control group considering mild/moderate dysautonomia (Mann

---

**Table 2 Demographic data and serum lipid levels in pathological and control groups**

| Group               | Age    | TC    | TG    | LI     | ApoA   | ApoB   |
|---------------------|--------|-------|-------|--------|--------|--------|
| Depression          | 50 ± 14.8 | 202.4 ± 49.6 | 88.1 ± 36.2 | 0.46 ± 0.2 | 155.7 ± 39.1 | 125.1 ± 49.7 |
| M                   | 49.8 ± 14.3 | 171.2 ± 40.5 | 93.7 ± 34.0 | 0.27 ± 0.1 | 161.3 ± 36.6 | 98.7 ± 11.9 |
| F                   | 50 ± 14.0 | 211.0 ± 48.8 | 86.4 ± 37.3 | 0.52 ± 0.2 | 154.1 ± 40.3 | 133.0 ± 54.0 |
| Anxiety             | 480 ± 17.7 | 190.7 ± 47.2 | 181.2 ± 81.5 | -0.18 ± 0.4 | 161.9 ± 56.9 | 169.9 ± 32.9 |
| M                   | 486 ± 16.2 | 201.0 ± 34.2 | 195.3 ± 93.3 | -0.22 ± 0.5 | 154.5 ± 56.4 | 172.8 ± 28.8 |
| F                   | 471 ± 20.2 | 177 ± 59.3 | 162.5 ± 61.3 | -0.13 ± 0.24 | 167.5 ± 59.2 | 166.1 ± 38.6 |
| Anxious-depressive disorder | 466 ± 13.8 | 160.9 ± 28.1 | 143.7 ± 19.5 | -0.09 ± 0.10 | 189.3 ± 41.1 | 125.9 ± 42.2 |
| M                   | 528 ± 106 | 148.3 ± 15.6 | 134.22 | -0.09 ± 0.12 | 170.8 ± 54.8 | 114.1 ± 43.1 |
| F                   | 414 ± 14.7 | 171.7 ± 33.0 | 152.1 ± 12.3 | -0.10 ± 0.08 | 205.1 ± 15.9 | 136 ± 41.9 |
| Eating Disorders    | 313 ± 7.06 | 197 ± 31.48 | 53.5 ± 25.6 | 0.65 ± 0.1 | 130.9 ± 44.5 | 156.5 ± 35.8 |
| M                   | 24 | 201 | 49 | 0.07 | 106 | 170 |
| F                   | 318 ± 7.02 | 197 ± 32.65 | 53.8 ± 26.6 | 0.65 ± 0.1 | 132.7 ± 45.7 | 155.5 ± 36.9 |
| Controls            | 505 ± 10.8 | 177.9 ± 19.9 | 119 ± 27.9 | 0.15 ± 0.2 | 135.7 ± 42.2 | 145.8 ± 33.5 |
| M                   | 506 ± 9.9 | 177.6 ± 18.3 | 123.6 ± 29.2 | 0.12 ± 0.2 | 146.4 ± 44.9 | 140.8 ± 36.0 |
| F                   | 503 ± 12.3 | 178.0 ± 12.3 | 112 ± 24.8 | 0.19 ± 0.1 | 119.7 ± 32.4 | 153.4 ± 28.5 |

Legend: Data regarding age and lipid blood levels of every group are reported [as mean and standard deviation(±)], referring to the entire group and to the gender. M = male; F = female; TC = total cholesterol; TG = triglycerides; LI = lipid index; ApoA and ApoB = apolipoproteins A and B.
Whitney test for \( n > 20, Z = 30 \ p < 0.001 \). In terms of average, the highest Ewing score was in the anxious-depressive disorder group. For more details, see Table 3.

With regards, in particular, to HRV, there was not a statistically significant difference among the pathological groups (\( p > 0.1 \)). When compared to the control group, only the depression and anxiety groups presented a statistically significant difference (\( p = 0.05 \)). The anxious-depressive group, in terms of mean value, is the group with the lowest HRV of the whole sample (33.1 ± 10.2). Considering the whole sample, the correlation between ANS and lipid metabolism has been investigated, referring in particular to HRV, with highly statistically significant results (\( p < 0.01 \)). HRV and LI presented a positive correlation: the anxious-depressive disorder group, in fact, presented the lowest LI (showing to be the group with the most severe triglycerides hyperproduction) and the lowest HRV. Correspondingly, this group was the one with the highest average of Ewing score. HRV has been found to be inversely related to the triglycerides levels and positively related to the cholesterol levels; these results confirmed the HRV-LI correlation.

**Table 3 Sample’s Ewing score**

| Group                  | Ewing score |
|------------------------|-------------|
| Depression             | 1.3 ± 0.8   |
| M                      | 1.4 ± 1.3   |
| F                      | 1.3 ± 0.7   |
| Anxiety                | 1.3 ± 0.9   |
| M                      | 1.1 ± 0.8   |
| F                      | 1.5 ± 0.9   |
| Anxious-depressive disorder | 2 ± 0.9    |
| M                      | 2.1 ± 0.9   |
| F                      | 1.8 ± 0.8   |
| Eating Disorders       | 1.5 ± 0.6   |
| M                      | 2           |
| F                      | 1.5 ± 0.6   |
| Controls               | 0.6 ± 0.7   |
| M                      | 0.7 ± 0.7   |
| F                      | 0.4 ± 0.5   |

Legend: The Ewing score of each group is reported [mean and standard deviation(±)], referring to the entire group and to the gender. M = male; F = female.
Apolipoproteins A presented a negative correlation to HRV. The opposite has been found for Apolipoproteins B. For more details, see Table 4.

**Conclusions**

Lipid metabolism and autonomic functioning seem to be related to the discussed psychiatric disorders. In a context of enhancing knowledge, the lipid index could represent another biomarker to be taken into consideration.

Our findings are far from being definitive, also considering the small sample size and some disparities in male and female distribution. Further studies are necessary.

**Abbreviations**

LI: Lipid index; GPs: general practitioners; DSM-IV-TR: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision; HRV: Heart rate variability; ED: Eating Disorders; ANS: Autonomic nervous system; CI: Cholesterol index; TI: Triglycerides index.

**Authors’ contributions**

EP collected data, interpreted the results, and helped draft the manuscript. ML, AL, WM assisted with collecting data, interpreting the results and drafting the manuscript. CC designed the study, interpreted the results, and helped draft the manuscript. All authors read and approved the final manuscript.

**Competing interests**

The authors declare that they have no competing interests.

**References**

1. Baywa WK, Asnis GM, Sanderson WC, Irfan A, van Praag HM: High cholesterol levels in patients with panic disorder. Am J Psychiatry 1992, 149:576-378.
2. Rafter D: Biochemical markers of anxiety and depression. Psychiatry Res 2001, 103:93-96.
3. Sevincok L, Buyukozturk A, Dereboy F: Serum lipids concentrations in patients with comorbid generalized anxiety disorder and major depressive disorder. Can J Psychiatry 2001, 46:68-71.
4. Agargun MY, Dulger H, Inci R, Kara H, Ozer OA, Sekereglu MR, Besiroglu L: Serum concentrations in obsessive-compulsive disorder patients with and without panic attacks. Can J Psychiatry 2004, 49:776-778.
5. Shin JY, Suls J, Martin R: Are Cholesterol and Depression Inversely Related? A meta-analysis of the association between two cardiac risk factors. Ann Behav Med 2008, 36:33-43.
6. Roehring M, Masheb RM, White MA, Gello CM: Dieting Frequency in Obese Patients With Binge Eating Disorder: Behavioral and Metabolic Correlates. Obesity 2009, 174:689-697.
7. Case T, Lemieux S, Kennedy SH, Lewis GF: Elevated plasma lipids in patients with binge eating disorders are found only in those who are anorexic. Int J Eat Disord 1999, 25:187-193.
8. Sullivan PF, Gendall KA, Bulik CM, Carter FA, Joyce PR: Elevated total cholesterol in bulimia nervosa. Int J Eat Disord 1998, 23:425-432.
9. Rosolova H, Podlipny J: Anxious-depressive disorders and metabolic syndrome. Vnitr Lek 2009, 55:650-652.
10. Maes M, Smith R, Christophe A, Vanderscaeghe E, Van Gastel A, Demedts P, Wauters A, Meltzer HY: Lower serum high-density lipoprotein cholesterol (HDL-C) in major depression and in depressed men with serious suicidal attempts: relationship with immune-inflammatory markers. Acta Psychiatr Scand 1997, 95:212-221.
11. Kim YK, Myint AM: Clinical application of low serum cholesterol as an indicator for suicide risk in major depression. J Affect Disord 2004, 81:161-166.
12. Peter H, Hand I, Hohagen F, Koenig A, Mittermayer C, Wohlfart M: Serum cholesterol level comparison: control subjects, anxiety disorder patients, and obsessive-compulsive disorder patients. Can J Psychiatry 2002, 47:557-561.
13. Nesse RM, Cameron OG, Curtis GC, Mc Cann DS, Huber-Smith MJ: Adrenergic function in patients with panic anxiety. Arch Gen Psychiatry 1984, 41:771-776.
14. Muraldo G, Casu M, Falchero M, Brugno A, Barone V, Cittero P, Ameri P, Andragnetti G, Birolli L, Capello F, Corraia R, Rodriguez G, Ferro AM: Alterations in the autonomic control of heart rate variability in patients with anorexia or bulimia nervosa: correlations between sympathovagal activity, clinical features, and leptin levels. J Endocrinol Invest 2007, 30:356-362.
15. Lachsh M, Stein D, Kaplan Z, Matar M, Faigin M, Korsanski L, Cohen H: Irreversibility of cardiac autonomic dysfunction in female adolescents diagnosed with anorexia nervosa after short- and long-term weight gain. World J Biol Psychiatry 2009, 10:509-511.
16. Kalk NJ, Nutt DJ, Lingford-Hughes AR: The role of central noradrenergic dysregulation in anxiety disorders: evidence from clinical studies. J Psychopharmacol 2011, 25:3-16.
17. Choi CJ, Kim KS, Kim CH: Reactivity of heart rate variability after exposure to colored lights in healthy adults with symptoms of anxiety and depression. Int J Psychophysiol 2011, 79:83-88.
18. Kop WL, Symowski SJ, Gottlieb SS: Depression in heart failure: biobehavioral mechanisms. Heart Fail Clin 2011, 7:23-38.
19. Möller-Leimkuhler AM: Higher comorbidity of depression and cardiovascular disease in women: a biopsychosocial perspective. World J Biol Psychiatry 2010, 11:922-933.
20. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Washington DC: American Psychiatric Press, Fourth Edition, Text Revision.
21. Ewing DJ, Clarke BF: Diagnosis and management of diabetic autonomic neuropathy. Br Med J 1982, 285:916-918.
22. Ziegler D, Laux G, Dannenh K, Spulker M, Mühlen H, Mayer P, Gries FA: Assessment of cardiovascular autonomic function: age-related normal...
ranges and reproducibility of spectral analysis, vector analysis, and standard tests of heart rate variation and blood pressure responses.

Diabetic Med 1992, 9:166-175.

23. Vinik AI, Erbas T, Pfeifer M, Feldman EL, Stevens MJ, Russell JW: Diabetic autonomic neuropathy. In The Diabetes Mellitus Manual: A Primary Care Companion to Ellenberg and Rifkin’s. 6 edition. Edited by: Inzucchi SE. New York: McGraw Hill; 2004.

24. National Heart, Lung and Blood Institute: National Cholesterol Education Program. Third Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). National Institutes of Health, September 2002 [http://www.nhlbi.nih.gov/guidelines/cholesterol/atp3full.pdf].

doi:10.1186/1476-511X-10-192

Cite this article as: Pistorio et al. Autonomic nervous system and lipid metabolism: findings in anxious-depressive spectrum and eating disorders. Lipids in Health and Disease 2011 10:192.